HOME >> BIOLOGY >> NEWS
Doctors failure to reevaluate asthma severity hurts wheezing sufferers

Doctors who do not periodically reevaluate their patients' asthma severity are failing to provide good care to asthma sufferers, report Johns Hopkins physicians May 20 at the American Thoracic Society's annual meeting.

"We found that doctors were not reevaluating their patient's underlying asthma severity estimates and that these estimates anchor their treatment decisions," says Gregory Diette, M.D., an assistant professor of pulmonary and critical care medicine at Hopkins. "Doctors need to frequently update their severity assessments in order to provide care that meets the patient's needs."

According to most treatment guidelines, doctors should base asthma therapy on an individual's symptoms prior to medication use, a profile known as underlying severity estimate. But how physicians' estimates influenced care has been a black box. To examine the issue, the Hopkins team gathered data from 1,510 patients who had moderate asthma, as determined by self-reported symptoms and treatment guidelines. Through surveys, they discovered that their doctors had classified 849 of them as having an underlying severity estimate of mild; they deemed the other 761 as moderate or greater.

When the researchers compared the two groups with National Asthma and Education Prevention Program (NAEPP) guidelines, they found that the lower the estimate, the worse the care. Doctors gave many more moderately asthmatic patients guidance and information about how to manage their symptoms and handle an attack, in comparison to mild asthmatics. Roughly 60 percent of the moderate cases, for example,had a peak flow meter, a device patients use frequently to measure lung capacity and adjust anti-asthma drugs to prevent severe episodes. Only 16 percent of the mildly asthmatic patients owned these devices.

"Doctors need to reevaluate patients periodically to ensure an accurate, up-to-date diagnosis, and ensure quality treatment," says Linda Wolfenden, M.D., presenter of the study
'"/>

Contact: Kate O'Rourke
korourke@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
19-May-2001


Page: 1 2

Related biology news :

1. Doctors miss chances to help pregnant women quit smoking
2. Doctors miss chance to advise women of vitamin that prevents birth defects, survey finds
3. Doctors perform more IVF treatments, but multiple births decline
4. Doctors aware of Tylenol-related liver risk - but is the public getting the message?
5. One In Three Doctors Recommends Herbal Supplements To Patients
6. Doctors Find Lead On Common Genes Which Can Lead To Bowel Cancer
7. Plant Doctors Find Genetic Solution For Papaya Growers
8. Phase Out Planned For One Of Top Five U.S. Pesticides, Plant Doctors Respond
9. New Heart-Attack Indicator Dramatically Improves Diagnostic Accuracy Of ER Doctors: TnT/Echocardiogram Combination Could Reduce Needless Admissions
10. Pump failure implicated in a form of dystonia
11. UCSD finds genetic time bomb in heart that leads to heart failure in some patients

Post Your Comments:
(Date:6/23/2015)... 2015 Research and ... the "Body-Worn Temperature Sensors Market - Global ... 2014 - 2020" report to their offering. ... the global body-worn temperature sensors market. The global ... the basis of types, care setting, patient demographic, ...
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market announces that ... featured segment on "Money on the Mark", scheduled to air ... June 20 th . The ... be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... ... 01, 2015 , ... The next-generation sequencing (NGS) clinical market is poised for ... diagnostics industry. BCC Research reveals in its new report that the market drivers of ... a growing need for better diagnostics as part of a molecular diagnostics trend. , ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
(Date:7/1/2015)... July 1, 2015 Isagenix International, a leading ... three Gold, three Silver, and three Bronze Stevie® Awards ... in Chicago this month.The ... business awards program in the U.S. ... strength in developing leaders, cultivating talent, creating a unified ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
Cached News: